McMillan Shakespeare (FRA:NMN) Research & Development: €0.0 Mil (TTM As of Dec. 2025)


FRA:NMN McMillan Shakespeare Ltd FRA:NMN
75 GF Score
Price €11.90
GF Value €15.08
Valuation Modestly Undervalued
! 13 Warning Signs
View Full Analysis

What is McMillan Shakespeare Research & Development?

McMillan Shakespeare FRA:NMN +3.48% 75 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates FRA:NMN with a GF Score™ of 75/100 and a GF Value™ of €15.08 (Modestly Undervalued). The stock has 13 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. McMillan Shakespeare's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

McMillan Shakespeare  (FRA:NMN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

McMillan Shakespeare Research & Development Related Terms

McMillan Shakespeare Research & Development Historical Data

* Premium members only.

The historical data trend for McMillan Shakespeare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

McMillan Shakespeare Research & Development Chart

McMillan Shakespeare Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

McMillan Shakespeare Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:NMN
75GF Score
McMillan Shakespeare Ltd FRA:NMN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

McMillan Shakespeare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
McMillan Shakespeare (FRA:NMN) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on McMillan Shakespeare and its competitors.
Is McMillan Shakespeare's Research & Development too high?
McMillan Shakespeare's current Research & Development is €0.0 Mil. Overall, McMillan Shakespeare has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does McMillan Shakespeare's Research & Development compare to KFY and RHI?
McMillan Shakespeare's Research & Development of €0.0 Mil can be compared against companies in the Business Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Business Services company?
A good Research & Development depends on the Business Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on McMillan Shakespeare and its competitors. McMillan Shakespeare's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is McMillan Shakespeare stock overvalued right now?
Based on GuruFocus' analysis, McMillan Shakespeare (FRA:NMN) is currently considered Modestly Undervalued. The stock's GF Value™ is €15.08, compared to a current price of €11.90 — trading 21.1% below its estimated fair value. The current Research & Development is €0.0 Mil. McMillan Shakespeare's overall GF Score™ is 75/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For McMillan Shakespeare (FRA:NMN), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is McMillan Shakespeare (FRA:NMN) Overvalued in 2026?

Based on GuruFocus' analysis, McMillan Shakespeare stock appears to be undervalued. The current stock price of €11.90 is trading 21.1% below its estimated GF Value™ of €15.08. GuruFocus considers McMillan Shakespeare to be Modestly Undervalued.

Key valuation signals for FRA:NMN:

  • Research & Development: €0.0 Mil
  • GF Value™: €15.08 vs. price of €11.90 (21.1% below fair value)
  • GF Score™: 75/100 with 13 warning signs

No single metric tells the full story. See the FRA:NMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

McMillan Shakespeare Business Description

Other Exchanges MMS:Australia
Address 360 Elizabeth Street, Level 21, The Tower, Melbourne Central, Melbourne, VIC, AUS, 3000
McMillan Shakespeare is a provider of salary packaging, novated leasing, disability plan management and support co-ordination, and fleet management services. It actively works to cross-sell its products to clients, for example, selling its salary packaging services to its fleet management customers in Australia and New Zealand. McMillan dominates Australia's salary packaging market together with Smartgroup (also covered by Morningstar), and is also a large provider of novated leasing services by volumes—together with Smartgroup and SG Fleet. The group has three operating segments: group remuneration services, asset management services, and plan and support services. Most of the group's revenue is generated from the group remuneration services segment.
75GF Score

Get the complete analysis for FRA:NMN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.90
Price
€15.08
GF Value